By Allison Krebs

“I’m legally blind without my glasses.”

Although often used hyperbolically to describe poor eyesight, this phrase is usually inaccurate. Legal blindness is a specific clinical and legal classification with precise criteria defined not by inconvenience, dependency on glasses, or difficulty spotting road signs at night. Rather, it is based on standardized measurements of vision performed after appropriate correction with glasses or contact lenses. In the United States, approximately 1.08 million people meet the criteria for legal blindness, and for many, no pair of glasses can help.¹

Understanding what legal blindness actually means, what causes it, and what scientists are now doing to reverse it requires unpacking how vision is measured, what these measurements reflect, and how damage to specific cells in the eye can lead to permanent vision loss.

How Vision Works: From Light to Perception

To understand why glasses can correct some forms of vision loss but not others, it helps to first understand how the visual system converts light into the images we see every day. Vision begins when light enters the eye through the cornea and pupil and is focused by the lens onto the retina, a thin, specialized layer of neural tissue that lines the back of the eye (Figure 1a). The retina contains photoreceptor cells, known as rods and cones, that convert light into electrical signals, a process called phototransduction. Rods are primarily responsible for vision in low-light conditions and peripheral vision, while cones enable color vision and the detection of fine detail, particularly in bright light. When light strikes a photoreceptor cell, it triggers a biochemical cascade that ultimately transmits a signal to downstream neurons. These signals pass first to bipolar cells, which serve as intermediaries between photoreceptors and retinal ganglion cells (Figure 1b). From here, these electrical signals are processed by retinal neurons called retinal ganglion cells.  Retinal ganglion cells have long projections called axons that carry electrical signals. The axons of retinal ganglion cells bundle together to form the optic nerve (Figure 1), which carries all visual information from the eye to the brain.

The two optic nerves from each eye meet at a structure called the optic chiasm at the base of the brain. At the optic chiasm, nerve fibers partially cross so that each hemisphere processes the opposite visual field. From there, these signals travel through relay stations in the thalamus to the primary visual cortex in the occipital lobe. The visual cortex is where the brain constructs a coherent image of the surrounding environment from the raw electrical signals generated by the retina (Figure 1a).^2,3

Clear vision depends on multiple components of this system working together. The cornea and lens must accurately focus incoming light, the retina must accurately detect and encode it, and visual pathways must transmit and correctly interpret the information. Alterations anywhere along this pathway can affect how clearly or completely a person sees the world. When damage occurs at the level of the photoreceptors, no lens or pair of glasses can compensate because the problem is not one of focus, but of signal generation itself. Although every component of the visual system contributes to sight, clinicians need objective ways to measure how well that system is functioning. Two measurements, visual acuity and visual field, form the foundation of eye examinations and ultimately help determine whether someone meets the legal definition of blindness.

Visual Acuity and Visual Field: How Vision is Measured

Visual acuity (VA) refers to the sharpness or clarity of central vision, or the ability to distinguish fine details when looking directly at an object. Measurements of VA are among the most familiar assessments in eye care, but they are frequently misunderstood. One of the most common methods used to assess VA is the Snellen chart, which contains rows of letters in decreasing sizes to measure an individual’s Snellen fraction  (Figure 2).⁴ VA depends on the cornea and lens precisely focusing light onto the retina, the photoreceptors in the fovea (Figure 1a) detecting fine detail, and the neural processing in the brain’s visual pathways to interpret the signals. Altogether, these functions reflect how well the visual system can resolve spatial detail under standardized conditions.

VA can be impacted at different points along the visual pathway. Refractive errors, such as myopia (nearsightedness) and hyperopia (farsightedness) are among the most common causes of reduced VA but can typically be fully corrected with glasses or contact lenses. Refractive errors occur when the shape of the cornea or the length of the eye prevents light from being properly focused on the retina. Cataracts, a clouding of the lens, are another common and largely correctable cause of reduced visual acuity. Surgical lens replacement restores clear vision in most cases (Figure 3). There are many measures of VA to determine how clearly objects are resolved in vision and is not limited to only nearsightedness and farsightedness. For example, peripheral visual acuity determines how clearly objects are resolved in peripheral vision.

Visual acuity alone does not capture all forms of vision loss. The visual field is assessed to evaluate how much of the surrounding environment can be detected when looking straight ahead, a distinct measurement from peripheral VA. An individual may retain sharp central vision while losing peripheral awareness, or vice versa, making visual field testing an essential complement to the Snellen chart. Similar to VA, visual field loss can result from damage at different locations along the visual pathway. Glaucoma, for example, is the most common cause of peripheral visual field loss. In glaucoma, damage to the optic nerve, often associated with elevated intraocular pressure (IOP), causes progressive loss of peripheral vision (Figure 3).

Together, visual acuity and visual field measurements do more than describe how well a person sees: they also form the basis of the legal definition of blindness.Legal blindness is not a medical diagnosis given by an optometrist or ophthalmologist, but a legal designation with an administrative purpose: it determines eligibility for workplace accommodations, disability benefits, and government assistance programs. Because of this, it relies on quantifiable criteria. The Social Security Administration defines legal blindness as best-corrected visual acuity of 20/200 or worse in the better-seeing eye, or a visual field of 20 degrees or less. A VA of 20/200 means that what the patient can visualize clearly at 20 feet, an individual with normal vision can see at 200 feet, representing a profound reduction in visual resolution.  Critically, legal blindness is determined by best-corrected vision: how well a person sees with glasses or contacts, not without them. If corrective lenses restore functional vision, the individual does not meet the definition, regardless of how poor their uncorrected vision may be.

Restoring What Glasses Cannot: The PRIMA Retinal Implant

Not all causes of vision loss can be corrected. Age-related macular degeneration (AMD) is a progressive disease in which photoreceptors in the macula (Figure 4), the region of the retina responsible for sharp central vision, gradually die. Because the damage in AMD is to the retina itself rather than to the optics of the eye, glasses or contact lenses cannot restore what has been lost. Patients with advanced AMD may see wavy lines, blind spots, or a dark area in the center of their vision (Figure 3). AMD exists in two forms: dry and wet. Dry AMD, the more common form, involves gradual thinning of the macula and accumulation of deposits called drusen. In its advanced stage, known as geographic atrophy, large patches of photoreceptors die, leaving permanent blind spots. Geographic atrophy affects approximately 5 million people worldwide and is responsible for roughly 20% of all cases of legal blindness in North America.⁵ Wet AMD, by contrast, involves abnorm\al blood vessel growth beneath the retina that can leak fluid and cause rapid vision loss. Wet AMD can typically be managed by regular injections that block blood vessel growth.

If legal blindness is defined by vision that corrective lenses cannot fix, the next question becomes: can anything else? For patients with advanced dry AMD, the answer has historically been no. The first FDA-approved treatments for geographic atrophy, pegcetacoplan (Syfovre) and avacincaptad pegol (Izervay), both approved in 2023, work by blocking the part of the immune response that drives retinal damage. These drugs represent important progress, but they merely slow disease progression. Neither drug restores vision that has already been lost.

In January 2026, the New England Journal of Medicine published results from the PRIMAvera trial for patients with advanced dry AMD.⁵ Rather than slow the death of photoreceptors, the PRIMA system bypasses them entirely. The PRIMA implant is a thin crystalline silicon chip, just 2mm by 2mm and 30μm thick. It is implanted beneath the retina, directly in the area where photoreceptors have died. The patient wears specialized glasses equipped with a camera that captures images and projects them onto the implant using near-infrared light (Figure 5). Each pixel in the implant converts this light into an electrical signal, stimulating the surviving bipolar cells: the next layer of neurons in the retinal circuit (Figure 1b). Because the implant ‘talks’ to bipolar cells rather than ganglion cells, it preserves more of the retina’s own signal processing. From the stimulated bipolar cells, the electrical impulses are sent through the optic nerve to the brain following the same pathway that healthy vision uses. The lenses of the glasses are transparent, so patients see a combination of their natural peripheral vision with overlaid prosthetic central vision simultaneously.

The results of the PRIMAvera trial were striking. Of 32 patients who completed 12 months of follow-up, 26 (81%) achieved a clinically meaningful improvement in VA (Figure 6). The mean improvement among these patients was equivalent to about 25.5 letters on a standard Snellen chart. Notably, one patient improved by 59 letters! Crucially, the implant did not damage remaining peripheral vision. Natural peripheral visual acuity after PRIMA implantation was equivalent to baseline, meaning that the device added central vision without taking away the peripheral vision that patients still had.

Clarity Over Hyperbole

The PRIMA trial is a proof of concept, not a cure, but it illustrates why precision in language matters. When “legally blind” is used as shorthand for poor eyesight, it obscures the reality of severe visual impairment and minimizes the experiences of individuals who meet the actual criteria. It also reinforces the false notion that vision exists on a simple continuum from “normal” to “blind.” Legal blindness describes a specific kind of loss: vision that persists even after the best available correction. This distinction is not merely semantic; it determines who qualifies for support, which therapies are appropriate, and, as the PRIMA trial demonstrates, which patients may one day qualify to have their vision restored. As research continues to uncover new ways to treat, and even reverse, vision loss, maintaining a precise definition of legal blindness remains essential for accurately describing and supporting those living with profound, lasting visual impairment.

TL; DR:

• Legal blindness is defined by best-corrected visual acuity and visual field.
• Not all vision loss can be corrected with glasses or contact lenses.
• Subretinal implant technology shows early promise for restoring vision in irreversible retinal disease.

---

Reference

1. Flaxman AD, Wittenborn JS, Robalik T, et al. Prevalence of Visual Acuity Loss or Blindness in the US. JAMA Ophthalmology. 2021;139(7). doi:10.1001/jamaophthalmol.2021.0527
2. Covington BP, Al Khalili Y. Neuroanatomy, Nucleus Lateral Geniculate. PubMed. Published 2020. Accessed July 7, 2026. https://www.ncbi.nlm.nih.gov/books/NBK541137/
3. Huff T, Prasanna Tadi. Neuroanatomy, Visual Cortex. Nih.gov. Published August 14, 2023. Accessed July 7, 2026. https://www.ncbi.nlm.nih.gov/books/NBK482504/
4. Caltrider D, Gupta A, Tripathy K. Evaluation Of Visual Acuity. PubMed. Published May 1, 2024. Accessed July 7, 2026. https://www.ncbi.nlm.nih.gov/books/NBK564307/
5. Holz FG, Le Mer Y, Muqit MMK, et al. Subretinal Photovoltaic Implant to Restore Vision in Geographic Atrophy Due to AMD. New England Journal of Medicine. Published online October 20, 2025. doi:10.1056/nejmoa2501396